A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males
Clinical Endocrinology · 2025-07 · 103 (1) · 89-96
DOI: 10.1111/cen.15223 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Endocrinology, online erschienen am 26.02.2025. Verfasst von Sankar Sinju und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Madurai Medical College & Govt Rajaji Hospital, Madurai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Testosterone, Transsexualism, Gender-Affirming Procedures. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
Testosterone is the only available gender affirming hormonal therapy (GAHT) for female‐to‐male (FtM) transsexuals, to alleviate gender dysphoria and to obtain desired masculinizing effects. The objective is to study the effect of two different formulations of testosterone‐ testosterone enanthate (TE) and testosterone undecanoate (TU) on various clinical, biochemical and hormonal parameters.
Design
This is a prospective randomized controlled trial conducted over a period of 28 months in a Transgender multi‐specialty clinic. Fifty‐eight testosterone naive transgender men, randomized into two groups, 29 received TE and the remaining 29 received TU. Patients and Measurements The variables assessed were cessation of menstrual cycles, onset of facial and body hair, deepening of voice, waist‐to‐hip ratio, clitoromegaly, muscle strength, hematological, lipid, liver functions and gonadal hormonal profile. The changes were compared at baseline, 6 months and 1 year following TE and TU and compared between the groups.
Results
Both groups had desired masculinizing effects at the end of 1 year. There was a statistically significant increase in hemoglobin, hematocrit, LDL cholesterol and testosterone levels with a simultaneous decrease in HDL and estradiol levels at 1 year in both the groups with no statistical significance between the groups, despite the lesser number of injections received by TU group than TE group (6 vs . 18).
Conclusion
Both TE and TU is safe, effective and well tolerated GAHT among FtM transsexuals with no significant differences in clinical, biochemical and hormonal parameters. Testosterone undecanoate was preferred at the end of 1 year due to its long dosing intervals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Madurai Medical College & Govt Rajaji Hospital, Madurai, Tamil Nadu, India.
- Department of Plastic Surgery, Madurai Medical College & Govt. Rajaji Hospital, Madurai, Tamil Nadu, India.
- Department of Psychiatry, Madurai Medical College & Govt. Rajaji Hospital, Madurai, Tamil Nadu, India.
- Department of Obstetrics and Gynecology, Madurai Medical College & Govt. Rajaji Hospital, Madurai, Tamil Nadu, India.
- Department of Urology, Madurai Medical College & Govt. Rajaji Hospital, Madurai, Tamil Nadu, India.
ORCID-Profile: Subbiah Sridhar
Zitieren
APA
Sinju, S., Sridhar, S., Sreenivasan, P., Paramasivam, S., Varadarajan, G., Mahalakshmi, N. K., Gnanasekharan, T., & Natarajan, V. (2025). A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males. Clinical Endocrinology, 103(1), 89-96. https://doi.org/10.1111/cen.15223
Vancouver
Sinju S, Sridhar S, Sreenivasan P, Paramasivam S, Varadarajan G, Mahalakshmi NK, et al. A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males. Clinical Endocrinology. 2025;103(1):89-96. doi:10.1111/cen.15223
BibTeX
@article{Sinju2025,
author = {Sinju, Sankar and Sridhar, Subbiah and Sreenivasan, Palaniyappan and Paramasivam, Sureshkumar and Varadarajan, Geethaanjali and Mahalakshmi, Nattanmai Krishnan and Gnanasekharan, Thangavel and Natarajan, Vasanthiy},
title = {A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males},
journal = {Clinical Endocrinology},
year = {2025},
volume = {103},
number = {1},
pages = {89--96},
doi = {10.1111/cen.15223}
}
EUVIMED